Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamadermatol.2019.0140 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tofacitinib in focus: Fascinating voyage from conventional formulations to novel delivery systems.
Int J Pharm
January 2025
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, Maharashtra 400056, India. Electronic address:
Tofacitinib, a Janus kinase (JAK) inhibitor, has emerged as a primary therapeutic agent for managing autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, dermatitis and ulcerative colitis. By inhibiting the phosphorylation of JAK enzymes, tofacitinib prevents their activation within the JAK-STAT signaling pathway, which is vital for inflammatory responses. However, the tofacitinib delivery presents significant challenges, including pH-dependent solubility, poor permeability and susceptibility to oral degradation.
View Article and Find Full Text PDFLetter to the Editor Regarding "Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance".
Rheumatol Ther
January 2025
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
A Response to: Letter to the Editor Regarding "Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance".
Rheumatol Ther
January 2025
Pfizer SLU, Madrid, Spain.
Oral colon-targeted responsive chitosan/pectin-based nanoparticles propels the application of tofacitinib in colitis therapy.
Sci Rep
January 2025
School of Basic Medicine, Qingdao Medical College, Qingdao University, Qingdao, China.
Tofacitinib (Tof), a commercially available pan-Janus kinases inhibitor, is approved for the treatment of moderate to severe ulcerative colitis. However, its clinical application is limited due to dose-dependent systemic side effects. The present study aims to develop an efficient oral colon-targeted drug delivery systems using prebiotic pectin (Pcn) and chitosan (Csn) polysaccharides as a shell, with Tof loaded into a Bovine Serum Albumin (BSA) core, and improving it with chondroitin sulfate (Chs), thus constructing Tof@BSA-Chs-CP nanoparticles (NPs).
View Article and Find Full Text PDFTrachyonychia secondary to pediatric alopecia areata responding to oral tofacitinib therapy: a case report and review of literature.
Int J Dermatol
January 2025
Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, India.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!